Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
camrelizumab + SHR9146 + apatinib
- Development stage
- Phase 1
- Lead developer
- Hengrui Therapeutics
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous, Oral
01
Overview
**Camrelizumab + SHR9146 + apatinib** is an investigational triple drug combination used in clinical research primarily for treating advanced solid tumors and various cancers. - **Camrelizumab** is a humanized monoclonal antibody that targets the programmed death-1 (PD-1) receptor, thereby blocking PD-1/PD-L1 interactions and activating the immune system to kill cancer cells. - **SHR9146** (sometimes referred to as SHR-1701 or as a code name) is an oral inhibitor of indoleamine 2,3- dioxygenase 1 (IDO1), involved in tryptophan metabolism and immune suppression. - **Apatinib** is a small molecule inhibitor targeting the vascular endothelial growth factor receptor 2 (VEGFR-2), thereby inhibiting angiogenesis (formation of new blood vessels) essential for tumor growth. This combination is developed by Jiangsu Hengrui Pharmaceuticals and is primarily intended for immunotherapy and targeted therapy for cancers such as hepatocellular carcinoma, non-small cell lung cancer, and other advanced solid tumors[1][2][3].
- Brand names
- camrelizumab (for SHR-1210)Aitan (for apatinib)
- Other names
- camrelizumab + SHR9146 + apatinib
02
Targets
IDO1 (Indoleamine 2,3-dioxygenase 1)PDCD1 (Programmed cell death protein 1 receptor)VEGFR2 (Vascular endothelial growth factor receptor 2)
Beyond the preview
Go deeper on camrelizumab + SHR9146 + apatinib.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on camrelizumab + SHR9146 + apatinib.